ArticleScientific reports2025
Discovery of clocinizine as a potential oral drug against Schistosoma mansoni infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Investigation of the Anti-Pathogens (Basel, Switzerland) · 2026Article
- A Multidimensional Evaluation of Sakuranetin againstACS omega · 2026Article
- Nanostructured Lipid Carriers Enable In Vivo Efficacy of Parthenolide inPharmaceutics · 2026Article
- Structural Exploitation of Cinnarizine Identified Novel Drug-Like Anthelmintic Agents AgainstACS infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Schistosomiasis, a disease caused by parasitic worms, imposes a significant global health burden, affecting over 240 million people, particularly in low-income regions. To meet the Sustainable Development Goals (SDG), the World Health Organization (WHO) emphasize the need for novel antischistosomal agents. In previous work we identified that cinnarizine, a first-generation antihistamine, has promising antischistosomal activity. This study investigates the therapeutic potential of clocinizine, a chlorinated analogue of cinnarizine, against Schistosoma mansoni. Both in vitro and in vivo studies were conducted to assess its efficacy and compare it to the standard-of-care drug, praziquantel. Clocinizine exhibited potent in vitro antiparasitic activity, with an EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.